Indoleamine 2, 3‐dioxygenase 1 promoter hypomethylation is associated with poor prognosis in patients with esophageal cancer

Indoleamine 2, 3‐dioxygenase 1 (IDO1) is a primary enzyme that generates immunosuppressive metabolites. It plays a major role in tumor immunology and is a potential immune‐based therapeutic target. We have reported that IDO1 protein expression was associated with an unfavorable clinical outcome in e...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiyozumi, Yuki, Baba, Yoshifumi, Okadome, Kazuo, Yagi, Taisuke, Ogata, Yoko, Eto, Kojiro, Hiyoshi, Yukiharu, Ishimoto, Takatsugu, Iwatsuki, Masaaki, Iwagami, Shiro, Miyamoto, Yuji, Yoshida, Naoya, Watanabe, Masayuki, Baba, Hideo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549929/
https://www.ncbi.nlm.nih.gov/pubmed/31012515
http://dx.doi.org/10.1111/cas.14028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549929/
https://www.ncbi.nlm.nih.gov/pubmed/31012515
http://dx.doi.org/10.1111/cas.14028

Ejemplares similares